Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 March 2007, Vol. 109, No. 6, pp. 2273-2274.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levy, O.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Levy, O.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

IMMUNOBIOLOGY

Comment on Sochorova et al, page 2553

Bruton tyrosine kinase (Btk): key for signaling via Toll-like receptor 8

Ofer Levy

1 CHILDREN'S HOSPITAL BOSTON/HARVARD MEDICAL SCHOOL

The contribution of Btk to innate immune responses of myeloid cells is poorly understood. In this issue of Blood, Sochorova and colleagues demonstrate that deficient Btk function selectively impairs dendritic cell cytokine induction in response to viral single-stranded RNAs that activate Toll-like receptor 8 (TLR-8).

The discovery of pathways that may be deficient in patients with susceptibility to infection is a key impetus to the study of human immunology. In 1952, Colonel Ogden Bruton1 first noted an absence of the {gamma}-globulin peak in the serum of a boy with recurrent infections, thereby describing an index case of X-linked agammaglobulinemia (XLA). Recombinant DNA techniques allowed for the identification of the gene defect in XLA patients leading to impaired function of the cytoplasmic tyrosine kinase named Bruton tyrosine kinase (Btk),2 expressed at all stages of B-cell lineage development. Thus, patients with defects in Btk have impaired B-cell production, have agammaglobulinemia, and present with recurrent infections.

Btk is also expressed by non-B cells, including myeloid cells, but its roles and contributions in this context are less clear. The recent characterization of the Toll-like receptor (TLR) family of transmembrane proteins that contribute to microbial recognition is a major breakthrough in our understanding of innate immunity3,4 and represents an opportunity to better define the roles of Btk in innate responses of myeloid cells. In the report by Sochorova and colleagues in this issue of Blood, the authors studied TLR-mediated responses of monocyte-derived dendritic cells (DCs) from patients with XLA compared with adult controls. Although responses to diverse agonists of TLRs 2 through 5 were normal, TNF-{alpha} and IL-6 responses to ssRNAs that activate via TLR-8 were markedly impaired. Treatment of normal DCs with the Btk-selective inhibitor LFM-A13 mimicked the phenotype of XLA cells, demonstrating selective impairment in TLR-8–mediated TNF-{alpha} and IL-6 production. A member of a subfamily of TLRs expressed in endosomes, TLR-8 serves to recognize viral single-stranded RNAs, such as those of influenza virus, as well as synthetic immunomodulatory imidazoquinoline compounds that mimic purines.5,6

From the standpoint of TLR-mediated cell activation, Sochorova et al have helped us delineate novel and distinct aspects of TLR-8–mediated signaling (see figure). Importantly, Btk has been shown to directly interact with the intracellular domain of TLR-8.7 It has also been recently demonstrated that TLR-8 agonists induce especially robust responses from human monocytes and DCs, including those derived from newborns that generally show impaired responses to many other stimuli.8 Taken as a whole, these studies suggest distinct pathways by which TLR-8 activates cells and position TLR-8 agonists as robust immune adjuvants.


Figure 1
View larger version (107K):
[in this window]
[in a new window]

 
Role of Btk in TLR-8–mediated ssRNA-induced TNF-{alpha} production from monocyte-derived DCs. Illustration by A. Y. Chen.

 
From a clinical perspective, it is notable that patients with XLA have a profound susceptibility to infection with Enteroviruses that contain ssRNAs, including echoviruses, Coxsackie viruses, and polioviruses.9 Thus, the study by Sochorova et al raises the possibility that impaired TLR-8–mediated signaling in DCs of patients with XLA may contribute to their susceptibility to Enteroviruses.

Much remains to be defined with respect to the roles of Btk in TLR signaling, a challenging but worthwhile task that is being pursued in cell culture lines and primary cells. Btk mediates TLR-4–induced phosphorylation of the TLR adaptor molecule Mal in THP-1 cells10 and contributes to TLR-2– and TLR-4–induced TNF-{alpha} production in human mononuclear cells.11 Further dissection of these pathways will define the specificity of innate immune pathways, providing further insights into human health and disease.

Footnotes

The author declares no conflicting financial interests. {blacksquare}

REFERENCES

  1. Bruton O. Agammaglobulinemia. Pediatrics 1952; 9:722–727.[Abstract/Free Full Text]

  2. Lindvall JM, Blomberg KE, Valiaho J, et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005; 203:200–215.[CrossRef][Medline] [Order article via Infotrieve]

  3. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311:1–16.[Medline] [Order article via Infotrieve]

  4. Gay NJ, Gangloff M, Weber AN. Toll-like receptors as molecular switches. Nat Rev Immunol 2006; 6:693–698.[CrossRef][Medline] [Order article via Infotrieve]

  5. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174:1259–1268.[Abstract/Free Full Text]

  6. Gibbard RJ, Morley PJ, Gay NJ. Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pH-dependent signaling. J Biol Chem 2006; 281:27503–27511.[Abstract/Free Full Text]

  7. Jefferies CA, Doyle S, Brunner C, et al. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem 2003; 278:26258–26264.[Abstract/Free Full Text]

  8. Levy O, Suter EE, Miller RL, Wessels MR. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006; 108:1284–1290.[Abstract/Free Full Text]

  9. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006; 85:193–202.[CrossRef][Medline] [Order article via Infotrieve]

  10. Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA. MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem 2006; 281:10489–10495.[Abstract/Free Full Text]

  11. Horwood NJ, Page TH, McDaid JP, et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 2006; 176:3635–3641.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Impaired Toll-like receptor 8–mediated IL-6 and TNF-{alpha} production in antigen-presenting cells from patients with X-linked agammaglobulinemia
Klára Sochorová, Rudolf Horváth, Daniela Rozková, Jirí Litzman, Jirina Bartunková, Anna Sedivá, and Radek Spísek
Blood 2007 109: 2553-2556. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levy, O.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Levy, O.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020